Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA replication in cancer cells.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows

A growing number of U.S. adults consider electronic cigarettes (e-cigarettes) more harmful than conventional cigarettes, UT Southwestern Medical Center researchers show in a study.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

YOU MAY BE INTERESTED IN

SITC seeks applications for two fellowships

As more people are surviving cancer, we must continue funding bold science

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login